



This statement has been developed and reviewed by the Women's Health Committee and approved by the RANZCOG Board and Council.

A list of Women's Health Committee Members can be found in [Appendix A](#).

Disclosure statements have been received from all members of this committee.

Disclaimer This information is intended to provide general advice to practitioners. This information should not be relied on as a substitute for proper assessment with respect to the particular circumstances of each case and the needs of any patient. This document reflects emerging clinical and scientific advances as of the date issued and is subject to change. The document has been prepared having regard to general circumstances.

First endorsed by RANZCOG: November 2006
Current: March 2019
Review Due: March 2022

Values: The evidence was reviewed by the Women's Health Committee (RANZCOG), and applied to local factors relating to Australia and New Zealand.

Background: This statement was first developed by Women's Health Committee in November 2006 and reviewed in March 2019.


Funding: The development and review of this statement was funded by RANZCOG.

Table of contents

1. Plain language summary	3
2. Summary of recommendations	3
3. The National HPV Vaccination Program	3
4. HPV Vaccines	4
4.1 Dosage	4
4.2 Safety and Clinical Efficacy	4
4.3 Target populations	5
4.4 Ongoing screening	5
4.5 Other considerations	5
5. References	6
6. Other suggested reading	6
7. Useful Links	6
8. Links to other College statements	7
9. Patient information	7
Appendix A Women's Health Commit a M m t	

The HPV vaccines are made from Virus Like Proteins (VLP) that do not contain live, attenuated or killed virus. Given by intramuscular injection the VLP induces an antibody response. If the vaccinated individual is exposed to live HPV, the antibody response protects that individual from infection.

None of the available HPV vaccines are therapeutic and therefore do not treat existing lesions.



1.

<https://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/hpv-immunisation-programme/hpv-vaccine>

National Cervical Screening Program: Guidelines for the management of screen-detected abnormalities, screening in specific p9heuessivnic abinr tvanagl3.915087uoen.0174499((A.98569(e)21.99038(ide3.01499(at)3.98567(iv)

Appendix A Women's Health Committee Membership

Appendix B Overview of the development and review process for this statement

i. Steps in developing and updating this statement

This statement was originally developed in November 2006 and was most recently reviewed in March 2019. The Women's Health Committee carried out the following steps in reviewing this statement:

Declarations of interest were sought from all members prior to reviewing this statement.

Structured clinical questions were developed and agreed upon.

An updated literature search to answer the clinical questions was undertaken.

At the November 2018 face-to

A declaration of interest form specific to guidelines and statements was developed by RANZCOG and approved by the RANZCOG Board in September 2012. The Women's Health Committee members

Appendix C Full Disclaimer

This information is intended to provide general advice to practitioners, and should not be relied on as a substitute for proper assessment with respect to the particular circumstances of each case and the needs of any patient.

This information has been prepared having regard to general circumstances. It is the responsibility of each practitioner to have regard to the particular circumstances of each case. Clinical management should be responsive to the needs of the individual patient and the particular circumstances of each case.

This information has been prepared having regard to the information available at the time of its preparation, and each practitioner should have regard to relevant information, research or material which may have been published or become available subsequently.

Whilst the College endeavours to ensure that information is accurate and current at the time of preparation, it takes no responsibility for matters arising from changed circumstances or information or material that may have become subsequently available.